Viking Therapeutics, Inc.
VKTX Nasdaq Pharmaceutical Preparations Financials FY2016โFY2025
Last close ยท Oct 23, 2026
$24.40
5.5%
Revenue
Total sales reported in the income statement.
$0.0M
vs prior year
Operating margin
Operating income as a share of revenue.
โ
Net income
Profit after all expenses, interest and tax.
โ$360M
Free cash flow
Cash from operations minus capital spending.
โ
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
$2.8B
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
On โ$4.67 EPS (TTM)
What Viking Therapeutics, Inc. does
No business description yet.
- Legal name
- Viking Therapeutics, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Feb 11, 2026
- Accession ยท CIK
- 0001193125-26-046876
0001607678
Revenue and margins
Viking Therapeutics, Inc. had $0.0M of revenue in fiscal 2025.
FY16
Revenue $0.0M
FY17
Revenue $0.0M
FY18
Revenue $0.0M
FY19
Revenue $0.0M
FY20
Revenue $0.0M
FY21
Revenue $0.0M
FY22
Revenue $0.0M
FY23
Revenue $0.0M
FY24
Revenue $0.0M
FY25
Revenue $0.0M
Q3 '23
Revenue $0.0M
Q4 '23
Revenue $0.0M
Q1 '24
Revenue $0.0M
Q2 '24
Revenue $0.0M
Q3 '24
Revenue $0.0M
Q4 '24
Revenue $0.0M
Q1 '25
Revenue $0.0M
Q2 '25
Revenue $0.0M
Q3 '25
Revenue $0.0M
Q4 '25
Revenue $0.0M
Q1 '26
Revenue $0.0M
Q2 '26
Revenue $0.0M
FY16
Gross โ
Operating โ
Net โ
FCF โ
FY17
Gross โ
Operating โ
Net โ
FCF โ
FY18
Gross โ
Operating โ
Net โ
FCF โ
FY19
Gross โ
Operating โ
Net โ
FCF โ
FY20
Gross โ
Operating โ
Net โ
FCF โ
FY21
Gross โ
Operating โ
Net โ
FCF โ
FY22
Gross โ
Operating โ
Net โ
FCF โ
FY23
Gross โ
Operating โ
Net โ
FCF โ
FY24
Gross โ
Operating โ
Net โ
FCF โ
FY25
Gross โ
Operating โ
Net โ
FCF โ
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY16
Net income โ$14.7M
FY17
Net income โ$20.6M
FY18
Net income โ$22.1M
FY19
Net income โ$25.8M
FY20
Net income โ$39.5M
FY21
Net income โ$55.0M
FY22
Net income โ$68.9M
FY23
Net income โ$85.9M
FY24
Net income โ$110M
FY25
Net income โ$360M
Q3 '23
Net income โ$22.5M
Q4 '23
Net income โ$24.6M
Q1 '24
Net income โ$27.4M
Q2 '24
Net income โ$22.3M
Q3 '24
Net income โ$24.9M
Q4 '24
Net income โ$35.4M
Q1 '25
Net income โ$45.6M
Q2 '25
Net income โ$65.6M
Q3 '25
Net income โ$90.8M
Q4 '25
Net income โ$158M
Q1 '26
Net income โ$158M
Q2 '26
Net income โ$128M
FY16
Diluted EPS โ$0.90
FY17
Diluted EPS โ$0.79
FY18
Diluted EPS โ$0.38
FY19
Diluted EPS โ$0.36
FY20
Diluted EPS โ$0.54
FY21
Diluted EPS โ$0.71
FY22
Diluted EPS โ$0.90
FY23
Diluted EPS โ$0.91
FY24
Diluted EPS โ$1.01
FY25
Diluted EPS โ$3.19
Q3 '23
Diluted EPS โ$0.23
Q4 '23
Diluted EPS โ$0.24
Q1 '24
Diluted EPS โ$0.26
Q2 '24
Diluted EPS โ$0.20
Q3 '24
Diluted EPS โ$0.22
Q4 '24
Diluted EPS โ$0.33
Q1 '25
Diluted EPS โ$0.41
Q2 '25
Diluted EPS โ$0.58
Q3 '25
Diluted EPS โ$0.81
Q4 '25
Diluted EPS โ$1.39
Q1 '26
Diluted EPS โ$1.37
Q2 '26
Diluted EPS โ$1.10
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY16
Return on capital โ
Return on equity โ183.2%
Return on assets โ101.3%
FY17
Return on capital โ
Return on equity โ191.4%
Return on assets โ112.3%
FY18
Return on capital โ
Return on equity โ14.2%
Return on assets โ13.6%
FY19
Return on capital โ
Return on equity โ9.0%
Return on assets โ8.8%
FY20
Return on capital โ
Return on equity โ15.1%
Return on assets โ14.6%
FY21
Return on capital โ
Return on equity โ24.6%
Return on assets โ23.5%
FY22
Return on capital โ
Return on equity โ39.7%
Return on assets โ36.3%
FY23
Return on capital โ
Return on equity โ34.8%
Return on assets โ32.0%
FY24
Return on capital โ
Return on equity โ17.9%
Return on assets โ17.2%
FY25
Return on capital โ
Return on equity โ47.3%
Return on assets โ44.3%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
FY16
Free cash flow โ
FY17
Free cash flow โ
FY18
Free cash flow โ
FY19
Free cash flow โ
FY20
Free cash flow โ
FY21
Free cash flow โ
FY22
Free cash flow โ
FY23
Free cash flow โ
FY24
Free cash flow โ
FY25
Free cash flow โ
FY16
Cash from operations โ$11.1M
Capital spending โ
FY17
Cash from operations โ$14.8M
Capital spending โ
FY18
Cash from operations โ$18.8M
Capital spending โ
FY19
Cash from operations โ$24.8M
Capital spending โ
FY20
Cash from operations โ$21.8M
Capital spending โ
FY21
Cash from operations โ$47.6M
Capital spending โ
FY22
Cash from operations โ$48.4M
Capital spending โ
FY23
Cash from operations โ$73.4M
Capital spending โ
FY24
Cash from operations โ$87.8M
Capital spending โ
FY25
Cash from operations โ$279M
Capital spending โ
Cash from operations
Capital spending
Q3 '23
Cash from operations โ$19.7M
Capital spending โ
Q4 '23
Cash from operations โ$17.6M
Capital spending โ
Q1 '24
Cash from operations โ$6.1M
Capital spending โ
Q2 '24
Cash from operations โ$28.5M
Capital spending โ
Q3 '24
Cash from operations โ$22.0M
Capital spending โ
Q4 '24
Cash from operations โ$31.2M
Capital spending โ
Q1 '25
Cash from operations โ$52.3M
Capital spending โ
Q2 '25
Cash from operations โ$47.1M
Capital spending โ
Q3 '25
Cash from operations โ$94.0M
Capital spending โ
Q4 '25
Cash from operations โ$85.3M
Capital spending โ
Q1 '26
Cash from operations โ$114M
Capital spending โ
Q2 '26
Cash from operations โ$125M
Capital spending โ
Cash from operations
Capital spending
Dividends, buybacks and share count
Viking Therapeutics, Inc. returned โ to shareholders in fiscal 2025. The diluted share count rose 3.3%.
FY16
Dividends โ
Buybacks $0.0M
FY17
Dividends โ
Buybacks โ
FY18
Dividends โ
Buybacks โ
FY19
Dividends โ
Buybacks โ
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks $6.8M
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY16
Diluted shares 0.02B
FY17
Diluted shares 0.03B
FY18
Diluted shares 0.06B
FY19
Diluted shares 0.07B
FY20
Diluted shares 0.07B
FY21
Diluted shares 0.08B
FY22
Diluted shares 0.08B
FY23
Diluted shares 0.09B
FY24
Diluted shares 0.11B
FY25
Diluted shares 0.11B
Balance sheet
Cash, debt and the ratios that show how comfortably Viking Therapeutics, Inc. can carry it.
FY16
Cash $3.1M
Debt โ
FY17
Cash $20.6M
Debt โ
FY18
Cash $302M
Debt โ
FY19
Cash $276M
Debt โ
FY20
Cash $248M
Debt โ
FY21
Cash $202M
Debt โ
FY22
Cash $155M
Debt โ
FY23
Cash $362M
Debt โ
FY24
Cash $903M
Debt โ
FY25
Cash $706M
Debt โ
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $202M | $155M | $362M | $903M | $706M |
| Current ratio | 24.0x | 7.6x | 19.2x | 33.1x | 9.3x |
| Quick ratio | 24.0x | 7.6x | 19.2x | 33.1x | 9.3x |
| Total assets | $211M | $169M | $368M | $908M | $716M |
| Total liabilities | $8.8M | $23.2M | $20.1M | $28.0M | $76.7M |
| Shareholders' equity | $202M | $145M | $348M | $880M | $639M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | 3 / 7 | 3 / 7 | 1 / 7 | 1 / 7 | 2 / 7 | 2 / 7 | 3 / 7 | 3 / 7 | 1 / 7 |
| Accruals ratio | โ25.2% | โ31.8% | โ2.0% | โ0.4% | โ6.6% | โ3.2% | โ10.8% | โ4.7% | โ3.5% | โ10.0% |
| Altman Z'' | โ15.24 | โ12.16 | 73.30 | 44.91 | 24.09 | 25.20 | 3.77 | 19.24 | 36.45 | 7.05 |
10 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Research and development | $9.0M | $13.7M | $19.0M | $23.6M | $31.9M | $45.0M | $54.2M | $63.8M | $102M | $345M |
| Operating income | โ$13.8M | โ$19.1M | โ$26.2M | โ$32.7M | โ$42.7M | โ$55.7M | โ$70.4M | โ$101M | โ$151M | โ$393M |
| Pretax income | โ | โ | โ | โ | โ | โ | โ | โ$85.9M | โ$110M | โ$360M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | โ$14.7M | โ$20.6M | โ$22.1M | โ$25.8M | โ$39.5M | โ$55.0M | โ$68.9M | โ$85.9M | โ$110M | โ$360M |
| Diluted EPS | โ$0.90 | โ$0.79 | โ$0.38 | โ$0.36 | โ$0.54 | โ$0.71 | โ$0.90 | โ$0.91 | โ$1.01 | โ$3.19 |
| Diluted shares | 0.02B | 0.03B | 0.06B | 0.07B | 0.07B | 0.08B | 0.08B | 0.09B | 0.11B | 0.11B |
| Cash flow | ||||||||||
| Cash from operations | โ$11.1M | โ$14.8M | โ$18.8M | โ$24.8M | โ$21.8M | โ$47.6M | โ$48.4M | โ$73.4M | โ$87.8M | โ$279M |
| Stock-based compensation | $1.8M | $1.5M | $2.6M | $3.7M | $5.8M | $6.1M | $8.7M | $16.8M | $29.7M | $40.8M |
| Share buybacks | $0.0M | โ | โ | โ | โ | โ | $6.8M | โ | โ | โ |
| Dividends and buybacks | $0.0M | โ | โ | โ | โ | โ | $6.8M | โ | โ | โ |
| Balance sheet | ||||||||||
| Cash and short-term investments | $3.1M | $20.6M | $302M | $276M | $248M | $202M | $155M | $362M | $903M | $706M |
| Finance lease liabilities | โ | โ | $0.0M | โ | โ | โ | โ | โ | โ | โ |
| Current assets | $14.0M | $21.9M | $302M | $284M | $256M | $211M | $167M | $367M | $907M | $716M |
| Current liabilities | $6.5M | $8.7M | $4.6M | $6.8M | $12.1M | $8.8M | $21.9M | $19.1M | $27.4M | $76.7M |
| Total assets | $14.5M | $22.1M | $302M | $284M | $257M | $211M | $169M | $368M | $908M | $716M |
| Total liabilities | $6.5M | $8.7M | $4.6M | $7.1M | $12.2M | $8.8M | $23.2M | $20.1M | $28.0M | $76.7M |
| Shareholders' equity | $8.0M | $13.5M | $298M | $277M | $244M | $202M | $145M | $348M | $880M | $639M |
| Returns | ||||||||||
| Return on capital employed | โ171.8% | โ141.6% | โ8.8% | โ11.8% | โ17.5% | โ27.6% | โ48.0% | โ28.9% | โ17.1% | โ61.5% |
| Return on equity | โ183.2% | โ191.4% | โ14.2% | โ9.0% | โ15.1% | โ24.6% | โ39.7% | โ34.8% | โ17.9% | โ47.3% |
| Return on assets | โ101.3% | โ112.3% | โ13.6% | โ8.8% | โ14.6% | โ23.5% | โ36.3% | โ32.0% | โ17.2% | โ44.3% |
| Return on tangible equity | โ183.2% | โ152.8% | โ7.4% | โ9.3% | โ16.2% | โ27.2% | โ47.4% | โ24.7% | โ12.5% | โ56.3% |
| Growth | ||||||||||
| Share count change | โ | 59.6% | 121.6% | 25.0% | 0.9% | 6.3% | โ0.5% | 22.8% | 15.6% | 3.3% |
| Financial health | ||||||||||
| Current ratio | 2.2x | 2.5x | 66.4x | 41.8x | 21.1x | 24.0x | 7.6x | 19.2x | 33.1x | 9.3x |
| Quick ratio | 2.2x | 2.5x | 66.4x | 41.8x | 21.1x | 24.0x | 7.6x | 19.2x | 33.1x | 9.3x |
| Quality scores | ||||||||||
| Piotroski F-score | โ | 3.0 | 3.0 | 1.0 | 1.0 | 2.0 | 2.0 | 3.0 | 3.0 | 1.0 |
| Altman Z'' | โ15.2 | โ12.2 | 73.3 | 44.9 | 24.1 | 25.2 | 3.8 | 19.2 | 36.4 | 7.1 |
| Accruals ratio | โ25.2% | โ31.8% | โ2.0% | โ0.4% | โ6.6% | โ3.2% | โ10.8% | โ4.7% | โ3.5% | โ10.0% |
Source: SEC EDGAR XBRL filings (CIK 0001607678). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.